Cd31 competitors and uses thereof
AssigneeEncefa
InventorsLaurence BRESSAC, Serge GUERREIRO, Damien TOULORGE
Life of this patent
Estimating the term…
Abstract
Isolated anti-human CD38 antibodies or antigen-binding fragment thereof; nucleic acids and expression vectors encoding the same. Also, compounds which specifically compete with CD31 for CD38 binding, for use in preventing and/or treating a disease selected from neurodegenerative diseases, neuroinflammatory diseases, inflammatory diseases, autoimmune diseases, metabolic diseases, ocular diseases, age-related diseases, cancer and metastasis in a subject in need thereof.
Claims21
1-15. (canceled)
An isolated anti-human CD38 antibody or antigen-binding fragment thereof, wherein said antibody or antigen-binding fragment thereof competes with CD31 and induces lysosomal exocytosis in a cell, that is inhibited in the presence of vacuolin-1.
A method of preventing and/or treating a disease in a subject in need thereof, comprising administering to said subject a compound which specifically competes with CD31 for CD38 binding, wherein said disease is selected from the group consisting of neurodegenerative diseases;
- neuroinflammatory diseases;
- inflammatory diseases;
- autoimmune diseases;
- metabolic diseases;
- ocular diseases;
- age-related diseases;
- and cancer and metastasis.
A method of increasing the level of at least one anti-inflammatory cytokine in a subject in need thereof, comprising administering to said subject a compound which specifically competes with CD31 for CD38 binding.
Dependencies are inferred from the claim text.